Overview

Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.

Phase:

PHASE2

Details

Lead Sponsor:

Sung Won Choi

Treatments:

Vorinostat